Single cell characteristics of patients with vaccine-related adverse reactions following inactivated COVID-19 vaccination

作者全名："Jiang, Manling; Yu, Haiqiong; Luo, Li; Zhang, Lei; Xiong, Anying; Wang, Junyi; Wang, Qianhui; Liu, Yao; Liu, Shengbin; Xiong, Ying; Yang, Pingchang; Chang, Christopher; Zhang, Jianquan; He, Xiang; Li, Guoping"

作者地址："[Jiang, Manling; Luo, Li; Zhang, Lei; Xiong, Anying; Wang, Junyi; Wang, Qianhui; Liu, Yao; Liu, Shengbin; He, Xiang; Li, Guoping] Southwest Jiaotong Univ, Peoples Hosp Chengdu 3, Lab Allergy & Precis Med, Chengdu Inst Resp Hlth,Affiliated Hosp, 82 Qinglong St, Chengdu 610031, Peoples R China; [Jiang, Manling; Luo, Li; Zhang, Lei; Xiong, Anying; Wang, Junyi; Wang, Qianhui; Liu, Yao; Liu, Shengbin; He, Xiang; Li, Guoping] ChongQing Med Univ, Dept Pulm & Crit Care Med, Affiliated Hosp, Chengdu Peoples Hosp Branch 3,Natl Clin Res Ctr Re, Chengdu, Peoples R China; [Yu, Haiqiong; Zhang, Jianquan] Sun Yat Sen Univ, Affiliated Hosp 8, Dept Pulm & Crit Care Med, Shenzhen, Peoples R China; [Xiong, Ying] Sichuan Friendship Hosp, Dept Pulm & Crit Care Med, Chengdu, Peoples R China; [Yang, Pingchang] Shenzhen Univ, Sch Med, Inst Allergy Immunol, State Key Lab Resp Dis,Allergy Div, Shenzhen, Peoples R China; [Chang, Christopher] Mem Healthcare Syst, Joe DiMaggio Childrens Hosp, Div Immunol Allergy & Rheumatol, Hollywood, FL USA; [Zhang, Jianquan] Sun Yat Sen Univ, Affiliated Hosp 8, Dept Pulm & Crit Care Med, 3025 Middle Shennan Rd, Shenzhen 518033, Peoples R China"

通信作者："He, X; Li, GP (通讯作者)，Southwest Jiaotong Univ, Peoples Hosp Chengdu 3, Lab Allergy & Precis Med, Chengdu Inst Resp Hlth,Affiliated Hosp, 82 Qinglong St, Chengdu 610031, Peoples R China.; Zhang, JQ (通讯作者)，Sun Yat Sen Univ, Affiliated Hosp 8, Dept Pulm & Crit Care Med, 3025 Middle Shennan Rd, Shenzhen 518033, Peoples R China."

来源：HUMAN VACCINES & IMMUNOTHERAPEUTICS

ESI学科分类：IMMUNOLOGY

WOS号：WOS:001093670200001

JCR分区：Q2

影响因子：4.1

年份：2023

卷号：19

期号：2

开始页：　

结束页：　

文献类型：Article

关键词：COVID-19 vaccine; fever; allergic shock; single-cell mRNA sequencing

摘要："A good safety and immunogenicity profile was reported in Phase I and II clinical trials of inactivated SARS-CoV-2 vaccines. Here, we report two cases associated with vaccine-associated adverse events, including one patient with fever and another with anaphylactic shock resulting from inactivated SARS-CoV-2 vaccination. Cell sub-types and the importance of genetic characteristics were assessed using single-cell mRNA sequencing and machine learning. Overall, the patient with fever showed a significant increase in the numbers of cytotoxic CD8 T cells and MKI67(high) CD8 T cells. A potential concurrent infection with the Epstein-Barr virus enhanced interferon type I responses to vaccination against the virus. STAT1, E2F1, YBX1, and E2F7 played a key role in the transcription regulation of MKI67(high) CD8 T cells. In contrast, the patient with allergic shock displayed predominant increases in the numbers of S100A9(high) monocytes, activated CD4 T cells, and PPBPhigh megakaryocytes. The decision tree showed that LYZ and S100A8 in S100A9(high) monocytes contributed to the degranulation of neutrophils and activation of neutrophils involved in allergic shock. PPBP and PF4 were major contributors to platelet degranulation. These findings highlight the diversity of adverse reactions following inactivated SARS-CoV-2 vaccination and show the emerging role of cellular subtypes and central genes in vaccine-associated adverse reactions."

基金机构："National Natural Science Foundation of China [81970026]; Natural Science Foundation of Sichuan Province [82000029]; Health Commission of Sichuan Province [23NSFSC1736, 19ZD002]; Chengdu High-level Key Clinical Specialty Construction Project [20PJ208]; Chengdu Science and Technology Bureau [ZX20201202020, 2021-YF09-00102-SN]; [2020-YF05-00003-SN]"

基金资助正文："This work was supported by the National Natural Science Foundation of China [81970026, 82000029], Natural Science Foundation of Sichuan Province [23NSFSC1736], Health Commission of Sichuan Province [19ZD002, 20PJ208], Chengdu High-level Key Clinical Specialty Construction Project [ZX20201202020], Chengdu Science and Technology Bureau [2021-YF09-00102-SN, 2020-YF05-00003-SN]."